
  
    
      
        Background_NNP
        We_PRP have_VBP been_VBN interested_JJ in_IN quantitative_JJ analysis_NN of_IN gene_NN
        expression_NN within_IN single_JJ cells_NNS and_CC the_DT distribution_NN of_IN that_DT
        expression_NN within_IN populations_NNS of_IN cells_NNS replicating_VBG in_IN
        culture_NN (_( e_SYM ._. g_SYM ._. ,_, )_) [_NN 1_CD 2_CD 3_CD ]_NN ._. Since_IN the_DT level_NN of_IN any_DT specific_JJ
        protein_NN within_IN a_DT cell_NN is_VBZ dynamic_JJ ,_, and_CC since_IN it_PRP is_VBZ difficult_JJ
        to_TO describe_VB cells_NNS in_IN tissue_NN culture_NN as_IN "_'' steady_JJ state_NN "_''
        entities_NNS ,_, describing_VBG gene_NN expression_NN in_IN cell_NN populations_NNS in_IN
        quantitative_JJ terms_NNS becomes_VBZ a_DT complex_JJ problem_NN ._. Here_RB we_PRP have_VBP
        explored_JJ the_DT relationship_NN of_IN SV_NNP 40_CD large_JJ T_NN antigen_NN (_( Tag_NNP )_)
        expression_NN as_IN a_DT function_NN of_IN cell_NN density_NN and_CC cell_NN cycle_NN
        duration_NN in_IN clonal_NN populations_NNS of_IN Tag-immortalized_NNP mouse_NN
        astrocytes_NNS ._. These_DT cells_NNS depend_VBP on_IN expression_NN of_IN T_NN antigen_NN
        for_IN viability_NN ._.
        Expression_NNP of_IN Tag_NNP in_IN mouse_NN cells_NNS under_IN selective_JJ
        conditions_NNS that_WDT do_VBP not_RB require_VB tumorigenic_JJ transformation_NN
        (_( e_SYM ._. g_SYM ._. ,_, transduction_NN by_IN retrovirus_JJ and_CC selection_NN for_IN drug_NN
        resistance_NN )_) produces_VBZ immortal_NN cell_NN lines_NNS with_IN limited_JJ
        transformation_NN phenotypes_NNS [_NN 4_CD 5_CD ]_NN ._. However_RB ,_, expression_NN of_IN
        Tag_NNP has_VBZ profound_JJ effects_NNS on_IN the_DT cell_NN cycle_NN ,_, significantly_RB
        reducing_VBG cell_NN doubling_VBG time_NN and_CC increasing_VBG saturation_NN
        density_NN [_NN 4_CD 5_CD 6_CD ]_NN ._. These_DT direct_JJ effects_NNS of_IN Tag_NNP result_NN from_IN
        binding_JJ and_CC inactivation_NN of_IN the_DT retinoblastoma_NN family_NN
        proteins_NNS (_( p_NN 130_CD ,_, Rb_NNP ,_, p_NN 107_CD )_) and_CC the_DT tumor_NN suppressor_NN ,_, p_NN 53_CD [_NN 7_CD
        8_CD 9_CD ]_NN ._. Tag_NNP is_VBZ rate_NN limiting_VBG for_IN G_NNP 
        1_CD transit_NN ,_, and_CC this_DT effect_NN (_( as_RB well_RB as_IN
        saturation_NN density_NN and_CC growth_NN in_IN soft_JJ agar_NN )_) is_VBZ Tag-dose_NNP
        dependent_JJ [_NN 3_CD 10_CD 11_CD 12_CD ]_NN ._. Since_IN the_DT cell_NN lines_NNS in_IN this_DT
        study_NN are_VBP capable_JJ of_IN entering_VBG a_DT quiescent_JJ state_NN at_IN
        saturation_NN density_NN [_NN 6_CD ]_NN ,_, one_PRP might_MD expect_VB that_IN the_DT levels_NNS
        of_IN Tag_NNP would_MD decrease_VB at_IN saturation_NN and_CC as_IN cells_NNS
        progressively_RB slow_JJ down_RB as_IN a_DT function_NN of_IN cell_NN density_NN ._.
        However_RB ,_, we_PRP have_VBP previously_RB noted_VBN that_IN the_DT Tag_NNP increased_VBD
        in_IN Tag-transformed_NNP NIH_NNP 3_CD T_NN 3_CD cells_NNS as_IN the_DT population_NN became_VBD
        more_RBR dense_JJ and_CC the_DT cell_NN cycle_NN time_NN increased_VBD during_IN
        exponential_NN growth_NN [_NN 11_CD ]_NN ._. For_IN some_DT cell_NN types_NNS ,_, like_IN
        fibroblasts_NNS and_CC lymphocytes_NNS ,_, G_NNP 
        0_CD cells_NNS have_VBP less_JJR cell_NN mass_NN than_IN cycling_NN
        cells_NNS ,_, and_CC one_PRP might_MD expect_VB that_IN Tag_NNP expression_NN would_MD
        decrease_VB as_IN the_DT G_NNP 
        1_CD phase_NN of_IN the_DT cycle_NN lengthened_VBN and_CC
        cells_NNS achieved_VBD confluence_NN ._. Since_IN Tag_NNP did_VBD not_RB decrease_VB
        simultaneously_RB with_IN an_DT increasing_VBG G_NNP 
        1_CD time_NN ,_, and_CC since_IN Tag_NNP was_VBD one_CD of_IN the_DT G_NNP 
        1_CD rate-limiting_JJ molecules_NNS ,_, the_DT activity_NN
        of_IN Tag_NNP must_MD have_VB been_VBN decreasing_VBG while_IN Tag_NNP levels_NNS
        increased_VBN ._. Thus_RB ,_, negative_JJ control_NN of_IN the_DT cell_NN cycle_NN as_IN a_DT
        function_NN of_IN cell_NN density_NN was_VBD dominant_JJ to_TO the_DT activity_NN of_IN
        Tag_NNP ._. Though_IN the_DT Tag-transformed_NNP NIH-_NNP 3_CD T_NN 3_CD cells_NNS could_MD not_RB
        maintain_VB a_DT monolayer_NN at_IN confluence_NN (_( did_VBD not_RB enter_VB G_NNP 
        0_CD )_) during_IN the_DT plateau_NN phase_NN of_IN growth_NN ,_,
        it_PRP was_VBD expected_VBN that_DT expression_NN would_MD eventually_RB plateau_NN or_CC
        decrease_VB ._.
        The_DT purpose_NN for_IN this_DT study_NN was_VBD to_TO explore_VB further_VB the_DT
        relationship_NN between_IN Tag_NNP expression_NN as_IN a_DT function_NN of_IN cell_NN
        cycle_NN time_NN and_CC cell_NN density_NN ._. We_PRP asked_VBD whether_IN Tag_NNP
        expression_NN in_IN immortalized_JJ mouse_NN cells_NNS always_RB increased_VBN as_IN
        a_DT function_NN of_IN G_NNP 
        1_CD time_NN during_IN exponential_NN growth_NN and_CC
        whether_IN levels_NNS eventually_RB decreased_VBD or_CC achieved_VBD a_DT steady_JJ
        state_NN level_NN at_IN high_JJ cell_NN density_NN ._. The_DT advantage_NN to_TO using_VBG
        astrocyte_NN lines_NNS is_VBZ that_IN many_JJ of_IN these_DT lines_NNS can_MD maintain_VB a_DT
        monolayer_NN in_IN culture_NN for_IN long_JJ periods_NNS of_IN time_NN [_NN 6_CD ]_NN ._. Since_IN
        Tag_NNP levels_NNS are_VBP significantly_RB determined_VBN by_IN the_DT strength_NN of_IN
        the_DT transcription_NN promoter_NN in_IN this_DT retroviral_NN system_NN [_NN 1_CD 11_CD
        ]_NN ,_, we_PRP examined_VBD cell_NN lines_NNS immortalized_JJ by_IN Tag_NNP transcribed_JJ
        from_IN two_CD different_JJ promoters_NNS ._. In_IN the_DT analysis_NN of_IN these_DT
        data_NNS ,_, we_PRP (_( 1_LS )_) explored_JJ the_DT relationship_NN between_IN expression_NN ,_,
        G_NNP 
        1_CD phase_NN time_NN ,_, and_CC cell_NN density_NN ,_, (_( 2_LS )_)
        asked_VBD whether_IN the_DT transcriptional_NN promoter_NN affected_VBD those_DT
        relationships_NNS ,_, (_( 3_LS )_) explored_JJ analytical_JJ methods_NNS for_IN
        describing_VBG expression_NN within_IN the_DT context_NN of_IN these_DT
        relationships_NNS ,_, and_CC (_( 4_LS )_) asked_VBD whether_IN the_DT "_'' intrinsic_JJ
        expression_NN potential_JJ "_'' of_IN Tag_NNP affected_VBD Tag_NNP expression_NN at_IN
        high_JJ cell_NN density_NN ._. The_DT results_NNS of_IN this_DT study_NN have_VBP practical_JJ
        implications_NNS for_IN the_DT use_NN of_IN cell_NN lines_NNS as_IN standards_NNS in_IN
        quantitative_JJ assays_NNS of_IN gene_NN expression_NN [_NN e_SYM ._. g_SYM ._. ,_, [_NN 3_CD ]_NN ]_NN ._.
      
      
        Results_NNS
        
          Characterization_NNP of_IN tkT_NN lines_NNS
          We_PRP have_VBP previously_RB characterized_VBN clonal_NN mouse_NN
          astrocyte_NN cell_NN lines_NNS ,_, immortalized_JJ by_IN transduction_NN of_IN
          SV_NNP 40_CD large_JJ T_NN antigen_NN expressed_VBD from_IN the_DT MoMuLV_NNP LTR_NNP [_NN 6_CD 13_CD
          ]_NN ._. Here_RB ,_, we_PRP compare_VBP variation_NN in_IN Tag_NNP levels_NNS in_IN 3_CD of_IN
          these_DT lines_NNS and_CC 3_CD additional_JJ lines_NNS (_( termed_VBD tkT_NN lines_NNS )_) ,_,
          immortalized_JJ with_IN Moloney_NNP Sarcoma_NNP Virus_NNP vectors_NNS
          expressing_VBG Tag_NNP from_IN an_DT internal_JJ herpes_NNS thymidine_NN kinase_NN
          (_( tk_NN )_) promoter_NN ._. The_DT astrocyte_NN lineage_NN of_IN the_DT LTR_NNP lines_NNS has_VBZ
          been_VBN published_VBN [_NN 6_CD 13_CD ]_NN ._. The_DT astrocyte_NN lineage_NN of_IN the_DT
          tkT_NN lines_NNS was_VBD confirmed_VBN by_IN the_DT presence_NN of_IN the_DT
          astrocyte-specific_JJ intermediate_JJ filament_NN protein_NN ,_, GFAP_NNP [_NN
          14_CD ]_NN (_( Figure_NN 1_LS )_) ._. All_DT of_IN the_DT lines_NNS contained_VBD GFAP_NNP ,_, whereas_IN
          NIH_NNP 3_CD T_NN 3_CD cells_NNS treated_VBN with_IN dibutyryl_NN cAMP_NN at_IN the_DT same_JJ
          level_NN as_IN the_DT astrocyte_NN lines_NNS did_VBD not_RB ._.
        
        
          Expression_NNP of_IN Tag_NNP
          To_TO determine_VB the_DT Tag_NNP expression_NN of_IN each_DT cell_NN line_NN at_IN a_DT
          single_JJ density_NN and_CC validate_NN cytometric_JJ measurements_NNS ,_,
          Western_NNP blotting_VBG was_VBD performed_VBN on_IN all_DT cell_NN lines_NNS and_CC
          compared_VBN to_TO purified_JJ ,_, recombinant_JJ Tag_NNP (_( Figure_NN 2_CD A_DT )_) ._.
          Lysates_NNP from_IN equal_JJ numbers_NNS of_IN cells_NNS were_VBD loaded_VBN on_IN the_DT
          electrophoresis_NNS gel_NN with_IN the_DT exception_NN of_IN P_NN 0_CD -_: 13_CD D_NNP tkT_NN #_# 13_CD ,_,
          which_WDT expressed_VBD the_DT lowest_JJS levels_NNS of_IN Tag_NNP ._. This_DT lysate_NN was_VBD
          loaded_VBN at_IN a_DT 2_CD -_: fold_VB higher_JJR cell_NN number_NN ._. Protein_NNP levels_NNS of_IN
          each_DT sample_NN and_CC the_DT recombinant_JJ Tag_NNP were_VBD adjusted_VBN to_TO
          equality_NN by_IN the_DT addition_NN of_IN NIH_NNP 3_CD T_NN 3_CD cell_NN extract_NN ._. The_DT
          presence_NN of_IN equal_JJ protein_NN levels_NNS in_IN each_DT lane_NN was_VBD
          confirmed_VBN by_IN staining_VBG the_DT blotted_JJ gel_NN with_IN Coomassie_NNP blue_JJ
          and_CC performing_VBG densitometry_NN ._. The_DT protein_NN levels_NNS were_VBD not_RB
          significantly_RB different_JJ (_( coefficient_NN of_IN variation_NN (_( CV_NNP )_) of_IN
          <_NN 9_CD %_NN )_) ._. Tag_NNP in_IN the_DT cell_NN lines_NNS migrated_JJ at_IN the_DT correct_JJ
          molecular_JJ weight_NN and_CC cross-reacting_JJ bands_NNS were_VBD not_RB
          detected_VBN ._. When_WRB the_DT Tag-specific_NNP fluorescence_NN (_( all_DT cell_NN
          cycle_NN phase_NN fractions_NNS )_) measured_VBN by_IN flow_NN cytometry_NN was_VBD
          compared_VBN to_TO the_DT intensity_NN of_IN Western_JJ blot_NN bands_NNS measured_VBN
          by_IN densitometry_NN ,_, the_DT two_CD measurements_NNS showed_VBD an_DT
          essentially_RB linear_JJ relationship_NN (_( Figure_NN 2_CD B_NNP )_) ._. Therefore_RB ,_,
          immunofluorescence_NN flow_NN cytometry_NN provides_VBZ an_DT unbiased_JJ
          estimate_NN of_IN the_DT relative_JJ levels_NNS of_IN Tag_NNP expression_NN for_IN the_DT
          range_NN of_IN measurements_NNS presented_VBN in_IN this_DT paper_NN ._.
        
        
          Effect_NN of_IN cell_NN density_NN related_VBD cell_NN cycle_NN control_NN
          on_IN expression_NN of_IN Tag_NNP
          A_DT priori_FW ,_, one_PRP might_MD expect_VB that_IN most_JJS cell_NN cycle_NN
          related_VBD genes_NNS will_MD be_VB less_JJR expressed_VBN in_IN growth_NN arrested_VBD ,_,
          confluent_NN ,_, or_CC G_NNP 
          0_CD cells_NNS relative_JJ to_TO proliferating_VBG
          cultures_NNS due_JJ to_TO a_DT generalized_JJ decrease_NN in_IN metabolic_JJ
          activity_NN ,_, cell_NN protein_NN content_NN ,_, and_CC cell_NN size_NN ._. However_RB ,_,
          based_VBN on_IN unpublished_JJ observations_NNS and_CC previous_JJ work_NN (_( see_VB
          Introduction_NNP ,_, )_) [_NN 11_CD ]_NN ,_, we_PRP expected_VBD that_IN the_DT Tag_NNP
          expression-cell_JJ density_NN profiles_NNS would_MD look_VB like_IN that_DT in_IN
          Figure_NN 3_CD ._. To_TO test_VB this_DT idea_NN ,_, we_PRP measured_VBD Tag_NNP expression_NN
          by_IN immunofluorescence_NN flow_NN cytometry_NN (_( see_VB Figure_NN 4_LS )_) in_IN 6_CD
          Tag-immortalized_NNP mouse_NN astrocyte_NN lines_NNS plated_JJ at_IN a_DT range_NN
          of_IN cell_NN densities_NNS and_CC cultured_JJ for_IN 2_CD -_: 3_CD days_NNS as_RB previously_RB
          described_VBD [_NN 15_CD ]_NN ._. The_DT upper_JJ densities_NNS ensured_JJ in_IN most_JJS
          cases_NNS that_IN the_DT cells_NNS would_MD be_VB in_IN either_DT the_DT "_'' transition_NN "_''
          or_CC "_'' plateau_NN "_'' phase_NN for_IN some_DT of_IN the_DT measurements_NNS ._. Since_IN
          Tag_NNP accumulates_NNS throughout_IN the_DT cell_NN cycle_NN ,_, populations_NNS
          with_IN different_JJ phase_NN fractions_NNS will_MD have_VB different_JJ
          average_JJ levels_NNS ,_, therefore_RB ,_, we_PRP measured_VBD Tag_NNP from_IN the_DT G_NNP 
          1_CD population_NN to_TO generate_VB measurements_NNS
          independent_JJ of_IN the_DT cell_NN cycle_NN phase_NN fraction_NN distribution_NN
          as_RB previously_RB described_VBD [_NN 3_CD ]_NN ._.
          Figure_NN 5_CD Ashows_NNP the_DT relationship_NN of_IN final_JJ cell_NN number_NN
          to_TO initial_JJ cell_NN number_NN for_IN two_CD combined_VBN experiments_NNS from_IN
          one_CD cell_NN line_NN ._. Plots_NNP like_IN this_DT were_VBD used_VBN to_TO determine_VB the_DT
          samples_NNS that_WDT represented_VBD the_DT exponential_NN portion_NN of_IN a_DT
          growth_NN curve_NN ._. The_DT slope_NN of_IN a_DT straight_JJ line_NN was_VBD calculated_VBN
          and_CC samples_NNS were_VBD chosen_VBN for_IN inclusion_NN when_WRB the_DT slope_NN was_VBD
          either_CC maximal_NN or_CC >_NN 2_CD ._. 0_CD when_WRB sufficient_JJ data_NNS could_MD not_RB
          be_VB obtained_VBN by_IN maximization_NN ._. The_DT %_JJ G_NNP 
          1_CD curves_NNS (_( 5_CD B_NNP )_) were_VBD used_VBN as_IN a_DT secondary_JJ
          guide_NN to_TO selecting_VBG the_DT exponential_NN data_NN ._. Figure_NN 5_CD Bshows_NNP
          that_IN the_DT G_NNP 
          1_CD fraction_NN increased_VBD as_IN a_DT function_NN of_IN
          final_JJ cell_NN density_NN but_CC that_IN more_RBR dense_JJ cells_NNS arrested_VBN
          with_IN a_DT significant_JJ fraction_NN of_IN S_NNP ,_, G_NNP 
          2_CD ,_, and_CC M_NNP cells_NNS ._. The_DT increase_NN in_IN the_DT G_NNP
          
          1_LS fraction_NN was_VBD expected_VBN as_IN we_PRP have_VBP
          demonstrated_VBN in_IN several_JJ cell_NN systems_NNS that_IN the_DT G_NNP 
          1_CD cell_NN cycle_NN phase_NN increases_NNS in_IN length_NN
          and_CC frequency_NN during_IN exponential_NN growth_NN as_IN a_DT function_NN of_IN
          cell_NN density_NN [_NN 11_CD 15_CD 16_CD ]_NN ._. This_DT change_NN in_IN G_NNP 
          1_CD can_MD be_VB demonstrated_VBN either_CC by_IN
          successive_JJ harvests_NNS from_IN cells_NNS plated_JJ at_IN a_DT single_JJ density_NN
          or_CC by_IN plating_VBG cells_NNS at_IN different_JJ densities_NNS and_CC harvesting_NN
          simultaneously_RB (_( as_IN in_IN this_DT study_NN )_) ._. The_DT presence_NN of_IN S_NNP
          phase_NN at_IN confluence_NN is_VBZ typical_JJ of_IN transformed_VBN cells_NNS ._.
          Figure_NN 5_CD (_( C_NNP ,_, D_NNP )_) shows_VBZ the_DT expression_NN profiles_NNS for_IN Tag_NNP
          versus_CC %_NN G_NNP 
          1_CD (_( C_NNP )_) and_CC final_JJ cell_NN density_NN (_( D_NNP )_) ._. The_DT
          exponential_NN region_NN defines_VBZ the_DT data_NNS used_VBN for_IN regression_NN
          measurements_NNS ._. Tag_NNP expression_NN at_IN terminal_NN cell_NN density_NN ,_,
          "_'' Final_NNP Tag_NNP "_'' ,_, was_VBD determined_VBN by_IN the_DT average_NN of_IN the_DT final_JJ
          two_CD samples_NNS (_( arrow_NN )_) ._.
          To_TO evaluate_VB expression_NN ,_, Tag_NNP measurements_NNS for_IN samples_NNS
          in_IN exponential_NN growth_NN (_( see_VB above_IN criteria_NNS )_) were_VBD subjected_VBN
          to_TO linear_JJ regression_NN on_IN final_JJ cell_NN density_NN to_TO generate_VB an_DT
          intercept_NN representing_VBG the_DT Tag_NNP level_NN at_IN a_DT hypothetical_JJ
          zero_CD cell_NN density_NN ._. This_DT value_NN for_IN each_DT experiment_NN was_VBD
          used_VBN to_TO normalize_VB data_NNS for_IN each_DT data_NNS set_VBN to_TO a_DT zero_CD cell_NN
          density_NN value_NN of_IN 100_CD and_CC thus_RB correct_JJ for_IN differences_NNS in_IN
          fluorescence_NN measurements_NNS obtained_VBN in_IN multiple_JJ
          experiments_NNS ,_, and_CC additionally_RB ,_, scale_NN the_DT data_NNS to_TO be_VB
          independent_JJ of_IN cell_NN line_NN specific_JJ expression_NN levels_NNS ._. The_DT
          normalized_JJ data_NN were_VBD then_RB combined_VBN for_IN replicate_VB or_CC
          triplicate_NN experiments_NNS and_CC subjected_VBN to_TO linear_JJ regression_NN
          on_IN the_DT fraction_NN of_IN G_NNP 
          1_CD cells_NNS and_CC final_JJ cell_NN densities_NNS ._. Data_NNS
          for_IN two_CD cell_NN lines_NNS are_VBP shown_VBN in_IN Figure_NN 6_CD ._. For_IN all_DT cell_NN
          lines_NNS ,_, the_DT slope_NN and_CC SE_NNP of_IN the_DT slope_NN were_VBD calculated_VBN and_CC
          plotted_VBD in_IN Figure_NN 7_CD ._. In_IN one_CD of_IN the_DT cell_NN lines_NNS ,_, the_DT slopes_NNS
          for_IN Tag_NNP versus_CC both_DT G_NNP 
          1_CD and_CC cell_NN density_NN were_VBD not_RB
          significantly_RB different_JJ from_IN zero_CD ._. For_IN another_DT line_NN ,_, the_DT
          slopes_NNS had_VBD significant_JJ positive_JJ values_NNS ,_, and_CC in_IN the_DT
          remaining_VBG 4_CD lines_NNS both_DT slopes_NNS were_VBD negative_JJ and_CC
          significant_JJ ._. Figure_NN 6_CD shows_VBZ data_NNS for_IN the_DT cell_NN line_NN that_WDT
          did_VBD not_RB differ_VB from_IN zero_CD and_CC a_DT representative_NN line_NN with_IN
          negative_JJ slopes_NNS ._. The_DT two_CD cell_NN lines_NNS that_WDT did_VBD not_RB display_VB
          a_DT decrease_NN in_IN Tag_NNP during_IN exponential_NN growth_NN were_VBD
          transformed_VBN with_IN retroviruses_NNS utilizing_VBG the_DT retroviral_NN
          LTR_NNP ._. Three_CD of_IN the_DT cell_NN lines_NNS that_WDT showed_VBD a_DT significant_JJ
          decrease_NN in_IN Tag_NNP during_IN exponential_NN growth_NN utilized_JJ
          retroviruses_NNS encoding_VBG transcription_NN of_IN Tag_NNP from_IN the_DT htk_NN
          promoter_NN ,_, which_WDT can_MD be_VB a_DT weak_JJ promoter_NN in_IN mouse_NN cells_NNS [_NN 1_CD
          11_CD ]_NN but_CC subject_JJ to_TO cell_NN line_NN specific_JJ effects_NNS (_( see_VB
          discussion_NN )_) ._. One_CD of_IN the_DT cell_NN lines_NNS showing_VBG a_DT significant_JJ
          decrease_NN in_IN Tag_NNP expression_NN was_VBD K_NNP 1_CD -_: 30_CD which_WDT encoded_JJ an_DT
          Rb-binding_NNP defective_JJ mutant_JJ Tag_NNP transcribed_JJ from_IN the_DT
          retroviral_NN LTR_NNP [_NN 6_CD ]_NN ._.
        
        
          Serum_NNP levels_NNS do_VBP not_RB affect_VB Tag_NNP expression_NN
          It_PRP is_VBZ possible_JJ that_IN Tag_NNP expression_NN could_MD be_VB regulated_VBN
          by_IN factors_NNS in_IN serum_NN ,_, and_CC that_IN these_DT factors_NNS could_MD be_VB
          progressively_RB depleted_VBN at_IN increasing_VBG cell_NN numbers_NNS ._. To_TO
          test_VB this_DT ,_, the_DT cell_NN line_NN in_IN which_WDT Tag_NNP control_NN was_VBD most_RBS
          sensitive_JJ to_TO density_NN ,_, P_NN 0_CD -_: 3_CD D_NNP tkT_NN #_# 5_CD ,_, was_VBD grown_VBN for_IN 3_CD days_NNS
          starting_VBG at_IN an_DT intermediate_JJ density_NN of_IN 10_CD 6_CD cells_NNS per_IN 10_CD
          cm_NN plate_NN with_IN varying_VBG concentrations_NNS of_IN serum_NN ranging_VBG
          from_IN 2_CD ._. 5_CD -_: 10_CD %_NN ._. Tag_NNP level_NN as_RB well_RB as_IN %_NN G_NNP 
          1_CD was_VBD equivalent_NN at_IN all_DT serum_NN levels_NNS
          (_( Table_NNP 2_LS )_) ._. Since_IN ,_, there_EX is_VBZ significantly_RB less_JJR serum_NN /_NN cell_NN
          in_IN 2_CD ._. 5_CD %_NN serum_NN samples_NNS ,_, we_PRP conclude_VBP that_IN factors_NNS in_IN serum_NN ,_,
          at_IN concentrations_NNS that_WDT maintain_VBP exponential_NN growth_NN ,_, do_VBP
          not_RB regulate_VB Tag_NNP levels_NNS in_IN these_DT cell_NN lines_NNS ._.
        
        
          Characterization_NNP of_IN density_NN and_CC growth_NN phase_NN
          effects_NNS on_IN Tag_NNP
          
            Tag_NNP expression_NN at_IN high_JJ cell_NN density_NN
            For_IN each_DT cell_NN line_NN ,_, the_DT levels_NNS of_IN Tag_NNP at_IN high_JJ cell_NN
            density_NN (_( either_CC transition_NN or_CC plateau_NN phase_NN )_) were_VBD
            significantly_RB lower_JJR than_IN during_IN exponential_NN growth_NN ._.
            This_DT level_NN ranged_VBD from_IN a_DT 12_CD -_: 63_CD %_NN decrease_NN compared_VBN to_TO
            the_DT hypothetical_JJ Tag_NNP level_NN of_IN 100_CD (_( normalized_JJ )_) at_IN 0_CD
            cell_NN density_NN (_( Table_NNP 1_LS )_) ._.
          
          
            Tag_NNP expression_NN at_IN zero_CD and_CC late_JJ cell_NN
            densities_NNS
            Figure_NN 8_CD Ashows_NNP the_DT correlation_NN plot_NN for_IN the_DT
            objective_NN ,_, "_'' expression_NN potential_JJ "_'' intercept_NN measurement_NN
            at_IN zero_CD cell_NN density_NN (_( defined_VBN above_IN )_) and_CC Tag_NNP measured_VBD
            from_IN Western_JJ blots_NNS in_IN Figure_NN 2_CD ._. The_DT Western_JJ blot_NN data_NNS
            represent_VBP a_DT sampling_VBG of_IN Tag_NNP expression_NN on_IN growing_VBG
            cultures_NNS ,_, in_IN late_JJ exponential_NN growth_NN ,_, and_CC thus_RB might_MD
            reflect_VB the_DT average_JJ ,_, qualitative_JJ experiment_NN ._. The_DT
            overall_JJ agreement_NN with_IN the_DT intercept_NN measurement_NN
            supports_VBZ the_DT use_NN of_IN this_DT objective_NN means_VBZ to_TO determine_VB
            expression_NN potential_JJ ,_, i_NNP ._. e_SYM ._. ,_, expression_NN that_WDT is_VBZ
            independent_JJ of_IN population_NN growth_NN /_NN density_NN effects_NNS ,_, in_IN
            quantitative_JJ analysis_NN ._. The_DT R_NN 2_CD value_NN for_IN the_DT regression_NN
            is_VBZ 79_CD %_NN ._. The_DT single_JJ outlier_NN represents_VBZ P_NN 0_CD -_: 17_CD D_NNP #_# 8_CD which_WDT is_VBZ
            the_DT only_JJ cell_NN line_NN that_WDT showed_VBD an_DT increase_NN in_IN Tag_NNP
            during_IN exponential_NN growth_NN and_CC so_RB would_MD not_RB be_VB expected_VBN
            to_TO fit_VB the_DT regression_NN as_RB well_RB ._. If_IN P_NN 0_CD -_: 17_CD D_NNP #_# 8_CD is_VBZ removed_VBN ,_,
            the_DT R_NN 2_CD is_VBZ 97_CD %_NN ._.
          
          
            Relationship_NNP of_IN Tag_NNP expression_NN as_IN a_DT function_NN of_IN
            cell_NN density_NN and_CC G_NNP 1_CD phase_NN time_NN
            An_DT increase_NN in_IN the_DT fraction_NN of_IN G_NNP 
            1_CD cells_NNS as_IN a_DT linear_JJ function_NN of_IN cell_NN
            density_NN is_VBZ a_DT common_JJ observation_NN in_IN this_DT laboratory_NN
            [_NN e_SYM ._. g_SYM ._. ,_, Figure_NN 4_CD B_NNP ,_, [_NN 11_CD 15_CD 16_CD ]_NN ]_NN ._. Figure_NN 8_CD Bshows_NNP that_IN
            there_EX is_VBZ a_DT correlated_JJ relationship_NN between_IN the_DT slopes_NNS ,_,
            i_NNP ._. e_SYM ._. ,_, changes_NNS in_IN Tag_NNP concentration_NN as_IN a_DT function_NN of_IN G_NNP 
            1_CD phase_NN time_NN is_VBZ correlated_JJ with_IN
            changes_NNS in_IN Tag_NNP as_IN a_DT function_NN of_IN cell_NN density_NN ._.
          
          
            Relationship_NNP between_IN final_JJ Tag_NNP and_CC the_DT expression_NN
            profile_NN for_IN G_NNP 1_CD
            Figure_NN 8_CD Cshows_NNP that_IN there_EX is_VBZ a_DT significant_JJ
            correlation_NN between_IN the_DT rate_NN of_IN change_NN of_IN T_NN antigen_NN as_IN
            a_DT function_NN of_IN cell_NN cycle_NN time_NN and_CC the_DT end-point_JJ
            expression_NN level_NN determined_VBN at_IN or_CC near_IN a_DT plateau_NN phase_NN
            in_IN these_DT experiments_NNS ._. Therefore_RB ,_, the_DT levels_NNS at_IN
            confluence_NN or_CC plateau_NN can_MD be_VB predicted_VBN by_IN the_DT direction_NN
            and_CC rate_NN of_IN change_NN during_IN exponential_NN growth_NN ._. Figure_NN
            8_CD Dshows_NNP that_IN the_DT same_JJ relationship_NN holds_VBZ true_JJ for_IN cell_NN
            density_NN ,_, as_IN would_MD be_VB expected_VBN from_IN Figure_NN 8_CD B_NNP ._.
          
          
            Control_NNP of_IN Tag_NNP expression_NN during_IN exponential_NN
            growth_NN is_VBZ independent_JJ of_IN the_DT intrinsic_JJ expression_NN
            potential_JJ
            Figures_NNS 8_CD Eand_NNP 8_CD Fshow_NNP the_DT regression_NN of_IN average_JJ Tag_NNP
            expression_NN (_( Western_JJ blot_NN in_IN Figure_NN 2_LS )_) on_IN the_DT G_NNP 
            1_CD and_CC cell_NN density_NN slopes_NNS ._.
            Regression_NNP of_IN data_NNS for_IN the_DT intercept_NN calculations_NNS
            (_( e_SYM ._. g_SYM ._. ,_, as_IN in_IN Figure_NN 8_CD A_DT )_) gave_VBD a_DT similar_JJ plot_NN ._. There_EX
            appears_VBZ to_TO be_VB no_DT relationship_NN between_IN the_DT intrinsic_JJ
            expression_NN "_'' strength_NN "_'' or_CC potential_NN and_CC change_NN in_IN Tag_NNP
            expression_NN as_IN a_DT function_NN of_IN G_NNP 
            1_CD phase_NN fraction_NN (_( time_NN )_) or_CC cell_NN
            density_NN ,_, i_NNP ._. e_SYM ._. ,_, growth_NN related_VBD control_NN of_IN Tag_NNP
            expression_NN ._.
          
        
      
      
        Discussion_NNP
        There_EX is_VBZ good_JJ evidence_NN that_IN quantitative_JJ changes_NNS in_IN gene_NN
        expression_NN are_VBP important_JJ for_IN some_DT regulatory_JJ genes_NNS ._. For_IN
        example_NN ,_, periodic_JJ quantitative_JJ changes_NNS in_IN the_DT levels_NNS of_IN
        cyclin_NN proteins_NNS that_WDT activate_VBP cyclin_NN dependent_JJ
        serine_NN /_NN threonine_NN kinases_NNS (_( cdk_NN 's_POS )_) appear_VB to_TO be_VB the_DT "_'' core_NN "_''
        cell_NN cycle_NN machinery_NN in_IN mammalian_JJ cells_NNS ._. In_IN this_DT case_NN ,_,
        cyclin_NN molecular_JJ concentration_NN is_VBZ directly_RB related_VBN to_TO cdk_NN
        activity_NN and_CC activity_NN is_VBZ directly_RB related_VBN to_TO cell_NN cycle_NN
        transition_NN rates_NNS [_NN 17_CD ]_NN ._. When_WRB regulatory_JJ proteins_NNS affect_VBP
        cell_NN processes_VBZ involved_VBN in_IN disease_NN ,_, measurement_NN of_IN
        molecular_JJ concentration_NN takes_VBZ on_IN added_JJ importance_NN ._. For_IN
        example_NN ,_, the_DT expression_NN of_IN a_DT number_NN of_IN oncogenes_NNS ,_,
        proto-oncogenes_JJ ,_, and_CC reduced_VBD or_CC absence_NN of_IN expression_NN of_IN
        recessive_JJ oncogenes_NNS has_VBZ been_VBN postulated_JJ to_TO provide_VB
        diagnostic_JJ and_CC /_NN or_CC prognostic_JJ information_NN in_IN human_JJ cancers_NNS
        [_NN e_SYM ._. g_SYM ._. ,_, [_NN 18_CD 19_CD 20_CD ]_NN ]_NN ._. Currently_RB ,_, cancer_NN gene_NN expression_NN
        research_NN is_VBZ seldom_RB done_VBN in_IN a_DT rigorously_RB quantitative_JJ
        manner_NN ,_, which_WDT may_MD contribute_VB to_TO the_DT sometimes_RB conflicting_JJ
        results_NNS [_NN 21_CD ]_NN ._. Much_JJ evidence_NN leads_VBZ to_TO the_DT conclusion_NN that_IN
        the_DT tumorigenic_JJ phenotype_NN of_IN mammalian_JJ cells_NNS is_VBZ markedly_RB
        affected_VBN by_IN quantitative_JJ changes_NNS in_IN expression_NN of_IN
        regulatory_JJ genes_NNS ._. In_IN experimental_JJ systems_NNS ,_, small_JJ shifts_NNS in_IN
        expression_NN can_MD have_VB profound_JJ consequences_NNS ._. For_IN instance_NN ,_, in_IN
        NIH_NNP 3_CD T_NN 3_CD cells_NNS ,_, expression_NN of_IN SV_NNP 40_CD large_JJ T_NN antigen_NN (_( Tag_NNP )_) at_IN
        high_JJ levels_NNS (_( ~_NN 2_CD ×_NN 10_CD 6_CD molecules_NNS per_IN G_NNP 
        1_CD cell_NN )_) decreases_VBZ the_DT G_NNP 
        1_CD phase_NN time_NN by_IN ~_NN 18_CD %_NN [_NN 3_CD 11_CD ]_NN ._. However_RB ,_,
        ~_NN 43_CD %_NN of_IN this_DT effect_NN can_MD be_VB accounted_VBN for_IN with_IN the_DT initial_JJ
        expression_NN of_IN ~_NN 6000_CD -_: 14_CD ,_, 000_CD molecules_NNS per_IN G_NNP 
        1_CD cell_NN and_CC ~_NN 87_CD %_NN can_MD be_VB accounted_VBN for_IN by_IN
        expression_NN of_IN ~_NN 103_CD ,_, 000_CD -_: 133_CD ,_, 000_CD molecules_NNS [_NN 3_CD 11_CD ]_NN ._.
        Previously_RB ,_, we_PRP measured_VBD the_DT relative_JJ dose_NN response_NN for_IN G_NNP
        
        1_LS transit_NN for_IN SV_NNP 40_CD Large_JJ T_NN antigen_NN
        expressed_VBD in_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS ._. In_IN this_DT work_NN ,_, the_DT levels_NNS of_IN Tag_NNP
        in_IN G_NNP 
        1_CD increased_VBD 18_CD %_NN during_IN exponential_NN
        population_NN growth_NN as_IN the_DT length_NN of_IN G_NNP 
        1_CD was_VBD increasing_VBG [_NN 11_CD ]_NN ._. Since_IN Tag_NNP is_VBZ
        rate-limiting_JJ for_IN G_NNP 
        1_CD transit_NN in_IN these_DT cells_NNS ,_, the_DT increase_NN
        in_IN transit_NN time_NN as_IN a_DT function_NN of_IN G_NNP 
        1_CD Tag_NNP concentration_NN represented_VBD an_DT
        apparent_JJ paradox_NN that_WDT is_VBZ resolved_VBN (_( in_IN the_DT simplest_JJS and_CC
        obvious_JJ manner_NN )_) by_IN stating_VBG that_IN additional_JJ rate-limiting_JJ
        entities_NNS operate_VBP to_TO set_VB the_DT G_NNP 
        1_CD transit_NN time_NN ._. One_CD easily_RB measured_VBN and_CC
        pervasive_JJ entity_NN that_WDT regulates_VBZ G_NNP 
        1_CD phase_NN time_NN is_VBZ cell_NN density_NN ,_, which_WDT is_VBZ
        taken_VBN as_IN a_DT surrogate_NN for_IN cell-cell_JJ contact_NN ._. This_DT effect_NN can_MD
        be_VB separated_JJ analytically_RB from_IN growth_NN factor_NN concentration_NN
        [_NN 15_CD 16_CD ]_NN and_CC therefore_RB ,_, appears_VBZ to_TO measure_VB independent_JJ
        cell_NN cycle_NN regulatory_JJ mechanisms_NNS ._. Our_PRP$ work_NN [_NN 6_CD 11_CD ]_NN and_CC
        most_RBS other_JJ work_NN indicates_VBZ that_IN the_DT cell_NN density_NN dependent_JJ
        mechanisms_NNS that_WDT negatively_RB regulate_VB cell_NN proliferation_NN are_VBP
        dominant_JJ to_TO Tag_NNP ._. Indeed_RB this_DT may_MD be_VB universal_JJ for_IN
        oncogenes_NNS ,_, since_IN we_PRP are_VBP not_RB aware_JJ of_IN instances_NNS when_WRB
        anchorage_NN dependent_JJ cells_NNS fail_VBP to_TO enter_VB a_DT plateau_NN phase_NN in_IN
        tissue_NN culture_NN ._.
        The_DT study_NN presented_VBN in_IN this_DT paper_NN represents_VBZ further_JJ
        investigation_NN into_IN the_DT effect_NN of_IN cell_NN density_NN on_IN gene_NN
        expression_NN ._. Cell_NNP lines_NNS were_VBD created_VBN by_IN incorporation_NN of_IN
        retroviral_NN vectors_NNS into_IN the_DT genome_NN and_CC expression_NN of_IN Tag_NNP
        from_IN either_DT the_DT retroviral_NN LTR_NNP (_( considered_VBN to_TO be_VB a_DT strong_JJ
        promoter_NN )_) or_CC the_DT herpes_NNS virus_NN thymidine_NN kinase_NN promoter_NN ,_,
        internal_JJ to_TO the_DT viral_JJ LTR_NNP [_NN 1_CD ]_NN ._. In_IN our_PRP$ established_VBN NIH_NNP
        3_CD T_NN 3_CD cell_NN line_NN ,_, Tag_NNP is_VBZ expressed_VBN from_IN the_DT htk_NN promoter_NN at_IN
        considerably_RB lower_JJR levels_NNS than_IN from_IN the_DT LTR_NNP for_IN a_DT
        considerable_JJ time_NN after_IN transduction_NN [_NN unpublished_JJ
        observations_NNS ,_, and_CC [_NN 11_CD ]_NN ]_NN ._. However_RB ,_, when_WRB a_DT large_JJ number_NN of_IN
        htk-_NN Tag_NNP astrocyte_NN clones_NNS were_VBD checked_VBN 100_CD days_NNS after_IN
        creation_NN ,_, the_DT expression_NN levels_NNS displayed_VBD a_DT very_RB large_JJ
        range_NN ,_, and_CC thus_RB we_PRP expect_VBP that_IN this_DT weak_JJ promoter_NN is_VBZ
        subject_JJ to_TO positional_JJ effects_NNS on_IN transcription_NN or_CC
        mutational_NN events_NNS that_WDT affect_VBP gene_NN expression_NN (_( unpublished_JJ
        data_NNS )_) ._. Polyclonal_NNP populations_NNS produced_VBN by_IN transduction_NN of_IN
        htk-_NN Tag_NNP vectors_NNS that_WDT were_VBD passaged_JJ without_IN selection_NN ,_,
        displayed_VBN expression_NN levels_NNS equivalent_JJ to_TO or_CC higher_JJR than_IN
        LTR-Tag_NNP cell_NN lines_NNS (_( Frisa_NNP and_CC Jacobberger_NNP ,_, unpublished_JJ
        data_NNS )_) ._. This_DT selection_NN for_IN increased_VBN Tag_NNP expression_NN makes_VBZ
        sense_NN given_VBN the_DT low_JJ growth_NN rate_NN of_IN primary_JJ mouse_NN astrocytes_NNS
        and_CC the_DT ability_NN of_IN Tag_NNP to_TO decrease_VB the_DT cell_NN cycle_NN time_NN [_NN 11_CD
        ]_NN and_CC increase_NN saturation_NN density_NN [_NN e_SYM ._. g_SYM ._. ,_, [_NN 4_CD 6_CD ]_NN ]_NN ._. In_IN this_DT
        study_NN ,_, the_DT expression_NN potential_NN of_IN cell_NN lines_NNS was_VBD not_RB
        related_VBN to_TO proliferation_NN related_VBD changes_NNS in_IN expression_NN of_IN
        Tag_NNP ,_, emphasizing_VBG that_DT clonal_NN variation_NN for_IN whatever_WDT reason_VBP
        (_( which_WDT includes_VBZ promoter_NN strength_NN )_) accounts_NNS for_IN the_DT large_JJ
        range_NN of_IN htk_NN related_VBD expression_NN ._.
        Making_VBG sense_NN of_IN a_DT quantitative_JJ description_NN of_IN the_DT role_NN
        of_IN Tag_NNP and_CC other_JJ regulatory_JJ proteins_NNS in_IN cell_NN cycle_NN
        regulation_NN and_CC cell_NN transformation_NN requires_VBZ either_CC that_IN all_PDT
        the_DT parameters_NNS affecting_VBG expression_NN are_VBP measured_VBN at_IN the_DT
        same_JJ time_NN so_IN that_IN differences_NNS can_MD be_VB accounted_VBN for_IN ,_, or_CC an_DT
        ability_NN to_TO compute_VB some_DT base_NN line_NN or_CC "_'' expression_NN potential_JJ "_''
        statistic_NN with_IN which_WDT to_TO evaluate_VB differences_NNS (_( e_SYM ._. g_SYM ._. ,_, between_IN
        cell_NN lines_NNS )_) ._. A_DT practical_JJ application_NN of_IN this_DT knowledge_NN is_VBZ
        the_DT ability_NN to_TO create_VB biological_JJ standards_NNS from_IN cell_NN lines_NNS
        that_WDT express_VBP varying_VBG levels_NNS of_IN a_DT given_VBN protein_NN and_CC then_RB use_VB
        these_DT in_IN quantitative_JJ and_CC /_NN or_CC longitudinal_NN experiments_NNS ._.
        Clearly_RB ,_, in_IN cases_NNS where_WRB gene_NN expression_NN varies_VBZ
        significantly_RB with_IN cell_NN density_NN (_( e_SYM ._. g_SYM ._. ,_, P_NN 0_CD -_: 3_CD DtkT_NNP #_# 5_LS )_) ,_, use_NN of_IN
        these_DT cells_NNS as_IN a_DT standard_NN in_IN a_DT longitudinal_NN study_NN would_MD
        require_VB that_IN the_DT standard_NN was_VBD measured_VBN at_IN the_DT same_JJ cell_NN
        density_NN for_IN each_DT experimental_JJ sampling_VBG ,_, or_CC that_IN a_DT derived_VBN
        statistic_NN (_( Expression_NNP /_NN Density_NNP or_CC Expression_NNP /_NN G_NNP 
        1_CD intercepts_NNS )_) is_VBZ used_VBN to_TO normalize_VB the_DT
        data_NNS ._. In_IN this_DT regard_NN ,_, the_DT good_JJ agreement_NN between_IN the_DT
        intercepts_NNS and_CC non-density_JJ corrected_VBN Western_JJ blot_NN data_NNS for_IN
        cell_NN lines_NNS varying_VBG over_IN a_DT 20_CD -_: fold_VB range_NN is_VBZ supportive_JJ ._.
        Originally_RB ,_, we_PRP pursued_VBD a_DT strategy_NN of_IN reduced_VBN Tag_NNP
        expression_NN from_IN the_DT htk_NN promoter_NN as_IN a_DT means_NN of_IN producing_VBG
        immortalized_JJ ,_, differentiated_JJ cells_NNS that_WDT may_MD have_VB a_DT reduced_VBN
        transformation_NN phenotype_NN ._. We_PRP noticed_VBD however_RB ,_, that_IN
        initially_RB slow_JJ growing_VBG cell_NN lines_NNS produced_VBN with_IN htk_NN driven_VBN
        gene_NN expression_NN needed_VBN to_TO be_VB cloned_VBN early_JJ to_TO prevent_VB
        overgrowth_NN of_IN more_JJR rapidly_RB growing_VBG cells_NNS that_WDT expressed_VBD
        high_JJ levels_NNS of_IN Tag_NNP ._. This_DT was_VBD not_RB true_JJ for_IN clonal_NN or_CC
        polyclonal_NN transductants_NNS that_WDT expressed_VBD Tag_NNP from_IN the_DT MoMuLV_NNP
        LTR_NNP ,_, which_WDT supports_VBZ a_DT high_JJ level_NN of_IN expression_NN (_( unpublished_JJ
        observations_NNS )_) ._. In_IN the_DT context_NN of_IN this_DT study_NN ,_, we_PRP wished_VBD to_TO
        explore_VB density_NN dependent_JJ expression_NN as_IN a_DT function_NN of_IN these_DT
        two_CD types_NNS of_IN transformants_NNS ._. The_DT data_NNS presented_VBN here_RB show_NN
        that_IN LTR_NNP driven_VBN Tag_NNP expressing_VBG cell_NN lines_NNS either_CC increase_NN
        Tag_NNP during_IN exponential_NN growth_NN despite_IN a_DT progressively_RB
        increasing_VBG G_NNP 
        1_CD phase_NN and_CC contact_NN inhibition_NN (_( density_NN )_)
        or_CC the_DT levels_NNS to_TO not_RB change_VB significantly_RB ,_, whereas_IN those_DT
        created_VBN with_IN the_DT htk_NN promoter_NN show_NN varying_VBG degrees_NNS of_IN
        reduced_VBN expression_NN ,_, that_WDT is_VBZ consistent_JJ in_IN magnitude_NN between_IN
        experiments_NNS ,_, as_IN the_DT cell_NN cycle_NN lengthens_VBZ ._. This_DT suggests_VBZ
        that_IN the_DT LTR_NNP is_VBZ less_JJR density_NN regulated_VBN than_IN the_DT htk_NN
        promoter_NN ,_, which_WDT is_VBZ subject_JJ to_TO down_RB regulation_NN as_IN the_DT cell_NN
        cycle_NN lengthens_VBZ during_IN contact_NN inhibition_NN of_IN growth_NN ._. The_DT
        single_JJ exception_NN is_VBZ the_DT pattern_NN of_IN expression_NN observed_VBD for_IN
        an_DT LTR_NNP driven_VBN line_NN expressing_VBG a_DT form_NN of_IN Tag_NNP that_WDT is_VBZ mutant_JJ
        in_IN binding_VBG the_DT Rb_NNP family_NN proteins_NNS [_NN e_SYM ._. g_SYM ._. ,_, [_NN 22_CD ]_NN ]_NN ._. This_DT
        density-dependent_JJ reduction_NN inTag_NN expression_NN was_VBD somewhat_RB
        surprising_JJ ._. We_PRP do_VBP not_RB know_VB the_DT half_JJ life_NN of_IN this_DT mutant_JJ T_NN
        antigen_NN (_( K_NNP 1_LS )_) ._. Since_IN it_PRP is_VBZ expressed_VBN at_IN levels_NNS that_WDT are_VBP 1_CD -_: 2_CD
        fold_VB that_IN of_IN wild-type_JJ Tag_NNP in_IN NIH_NNP 3_CD T_NN 3_CD cells_NNS [_NN 23_CD ]_NN ,_, we_PRP
        would_MD not_RB expect_VB that_IN the_DT half_JJ life_NN was_VBD significantly_RB lower_JJR
        than_IN that_DT of_IN wild_JJ type_NN ._. Alternatively_RB ,_, the_DT cell_NN line_NN used_VBN
        here_RB is_VBZ a_DT low_JJ expressing_VBG cell_NN line_NN (_( <_NN 2_CD fold_VB above_IN the_DT
        lowest_JJS expressing_VBG cell_NN line_NN )_) ._. Thus_RB ,_, in_IN this_DT cell_NN line_NN ,_, for_IN
        unknown_JJ reasons_VBZ the_DT protein_NN could_MD be_VB less_RBR stable_JJ ._. If_IN the_DT
        idea_NN that_DT transcription_NN strength_NN mainly_RB drives_VBZ Tag_NNP
        expression_NN is_VBZ kept_VBN as_IN the_DT working_VBG hypothesis_NNS ,_, then_RB there_RB
        are_VBP at_IN least_JJS three_CD possibilities_NNS to_TO explain_VB the_DT K_NNP 1_CD data_NNS :_: 1_LS )_)
        the_DT K_NNP 1_CD protein_NN has_VBZ a_DT mildly_RB shorter_JJR half-life_NN and_CC the_DT small_JJ
        difference_NN results_NNS in_IN a_DT different_JJ phenotype_NN vis-à-vis_JJ the_DT
        density_NN related_VBD expression_NN ;_: 2_LS )_) failure_NN to_TO bind_NN Rb_NNP family_NN
        members_NNS significantly_RB affects_VBZ the_DT half-life_NN during_IN
        exponential_NN growth_NN ;_: 3_LS )_) the_DT LTR_NNP vectors_NNS can_MD occasionally_RB
        display_VB integration_NN position_NN effects_NNS that_IN in_IN this_DT special_JJ
        case_NN was_VBD subject_JJ to_TO density_NN dependent_JJ control_NN that_WDT is_VBZ
        different_JJ from_IN most_JJS LTR_NNP driven_VBN cell_NN populations_NNS ._.
        Both_DT the_DT promoters_NNS as_RB well_RB as_IN the_DT protein_NN investigated_VBN
        here_RB are_VBP viral_JJ ._. The_DT cells_NNS are_VBP dependent_JJ on_IN Tag_NNP expression_NN ,_,
        and_CC so_RB there_EX is_VBZ significant_JJ selective_JJ pressure_NN against_IN
        extinction_NN of_IN Tag_NNP expression_NN ._. Effects_NNPS of_IN viral_JJ promoters_NNS
        may_MD reflect_VB the_DT evolution_NN of_IN the_DT viruses_NNS and_CC their_PRP$ hosts_NNS ._.
        We_PRP have_VBP additional_JJ evidence_NN that_IN the_DT same_JJ type_NN of_IN density_NN
        effects_NNS (_( i_NNP ._. e_SYM ._. ,_, changes_NNS in_IN gene_NN expression_NN detected_VBD
        continuously_RB during_IN exponential_NN growth_NN )_) may_MD operate_VB on_IN
        native_JJ proteins_NNS ._. Tag_NNP immortalized_JJ human_JJ tracheal_NN epithelial_NN
        (_( HTE_NNP )_) cells_NNS grown_VBN at_IN different_JJ densities_NNS and_CC assayed_JJ for_IN
        cytokeratins_NNS 6_CD and_CC 18_CD showed_VBD a_DT density_NN dependent_JJ decrease_NN
        in_IN cytokeratin_NN immunoreactivity_NN and_CC a_DT concomitant_NN increase_NN
        in_IN %_NN G_NNP 
        1_CD both_DT in_IN normal_JJ growth_NN medium_NN and_CC in_IN
        differentiation_NN medium_NN (_( Frisa_NNP &_CC Jacobberger_NNP ,_,
        unpublished_JJ )_) ._. Additionally_RB ,_, the_DT expression_NN levels_NNS of_IN cyclin_NN
        B_NNP 1_CD are_VBP lower_JJR in_IN replicating_VBG Hela_NNP cells_NNS at_IN high_JJ cell_NN density_NN
        (_( Soni_NNP &_CC Jacobberger_NNP ,_, unpublished_JJ results_NNS )_) ._. It_PRP is_VBZ
        conceivable_JJ that_IN other_JJ proteins_NNS that_WDT are_VBP at_IN high_JJ levels_NNS in_IN
        density-arrested_JJ cells_NNS may_MD be_VB positively_RB regulated_VBN by_IN
        density_NN during_IN exponential_NN growth_NN ._. There_EX are_VBP many_JJ papers_NNS
        that_WDT describe_VBP genes_NNS that_WDT are_VBP up_RB or_CC down_RB regulated_VBN at_IN
        confluence_NN ._. Several_JJ recent_JJ papers_NNS identify_VBP genes_NNS that_WDT are_VBP
        up-regulated_JJ by_IN cell_NN density_NN ._. These_DT include_VBP
        TEM_NNP 1_CD /_NN endosialin_NN ,_, IGF-_NNP 1_CD ,_, IGF-_NNP 1_CD R_NN ,_, IGFBP-_NNP 2_CD ,_, Bak_NNP ,_, drp_NN ,_, SP_NNP 1_CD ,_, p_NN 27_CD
        Kip_NNP 1_CD [_NN 24_CD 25_CD 26_CD 27_CD 28_CD ]_NN ._. However_RB ,_, cell_NN context_NN differences_NNS
        are_VBP apparent_JJ [_NN e_SYM ._. g_SYM ._. IGFR_NNP ,_, [_NN 29_CD ]_NN ]_NN ,_, and_CC one_CD study_NN used_VBD
        several_JJ cell_NN lines_NNS and_CC demonstrated_VBN distinct_JJ effects_NNS of_IN the_DT
        cell_NN genetic_JJ background_NN [_NN 25_CD ]_NN ._. Down-regulated_NNP genes_NNS
        include_VBP bFGF_NN ,_, FGF-_NNP 2_CD ,_, Topoisomerase_NNP II-α_NNP ,_, EGFR_NNP ,_, ,_, human_JJ
        HDAC_NNP 1_CD ,_, as_RB well_RB as_IN cell_NN cycle_NN regulatory_JJ genes_NNS among_IN others_NNS
        [_NN 30_CD 31_CD 32_CD 33_CD 34_CD 35_CD 36_CD 37_CD ]_NN ._. Regions_NNP in_IN the_DT bFGF_NN promoter_NN
        have_VBP been_VBN identified_VBN as_IN associated_VBN with_IN density-dependent_JJ
        down-regulation_JJ of_IN bFGF_NN [_NN 31_CD ]_NN ._. The_DT IGF-II_NNP P_NN 3_CD promoter_NN is_VBZ
        down-regulated_JJ as_IN a_DT function_NN of_IN cell_NN density_NN ,_, and_CC a_DT 7_CD -_: base_NN
        pair_NN sequence_NN has_VBZ been_VBN identified_VBN that_WDT plays_VBZ a_DT critical_JJ
        role_NN in_IN this_DT down-regulation_JJ [_NN 32_CD ]_NN ._. Neither_DT the_DT MoMuLV_NNP
        LTR_NNP or_CC the_DT htk_NN promoters_NNS encode_NN this_DT sequence_NN ,_, although_IN
        both_DT encode_NN a_DT 10_CD -_: base_NN pair_NN sequence_NN that_WDT is_VBZ identical_JJ to_TO
        the_DT P_NN 3_CD sequence_NN with_IN an_DT insertion_NN of_IN 3_CD base_NN pairs_NNS at_IN
        position_NN -_: 1081_CD ._. Most_JJS studies_NNS focus_VBP on_IN transcription_NN and_CC /_NN or_CC
        protein_NN levels_NNS ._. Fewer_JJR studies_NNS have_VBP addressed_VBN translation_NN ,_,
        however_RB ,_, iso-forms_JJ of_IN c-myc_JJ and_CC FGF-_NNP 2_CD are_VBP translationally_RB
        regulated_VBN by_IN cell_NN density_NN [_NN 34_CD ]_NN ._. For_IN many_JJ of_IN these_DT genes_NNS ,_,
        down_RB regulation_NN at_IN confluence_NN is_VBZ not_RB surprising_JJ (_( e_SYM ._. g_SYM ._. ,_, cell_NN
        proliferation_NN associated_VBN genes_NNS )_) ,_, and_CC upregulation_NN of_IN
        differentiation_NN specific_JJ genes_NNS at_IN confluence_NN is_VBZ equally_RB
        unsurprising_JJ ._. However_RB ,_, a_DT glance_NN at_IN the_DT literature_NN does_VBZ not_RB
        suggest_VB that_IN any_DT quick_JJ classification_NN or_CC generalizations_NNS
        should_MD be_VB made_VBN ._.
        Regulation_NNP of_IN protein_NN levels_NNS is_VBZ multi-factorial_JJ ._.
        Transcription_NNP ,_, translation_NN ,_, protein_NN stability_NN and_CC
        degradation_NN are_VBP involved_VBN ._. Tag_NNP levels_NNS in_IN rapidly_RB growing_VBG
        polyclonal_NN cell_NN lines_NNS appear_VBP to_TO be_VB set_VBN primarily_RB by_IN
        transcription_NN [_NN 11_CD 12_CD ]_NN ._. However_RB ,_, as_IN discussed_VBN above_IN ,_, Tag_NNP
        levels_NNS in_IN clonal_NN cell_NN lines_NNS produced_VBN with_IN the_DT weak_JJ htk_NN
        promoter_NN and_CC generated_VBN from_IN slowly_RB growing_VBG primary_JJ cells_NNS
        are_VBP related_VBN to_TO clonality_NN ._. SV_NNP 40_CD Tag_NNP is_VBZ a_DT long-lived_JJ protein_NN
        with_IN a_DT half-life_NN variously_RB measured_VBD at_IN 48_CD -_: 90_CD hrs_NNS ._. The_DT long_JJ
        half-life_NN of_IN Tag_NNP would_MD not_RB normally_RB implicate_VB protein_NN
        stability_NN ,_, however_RB ,_, the_DT magnitude_NN of_IN changes_NNS that_IN we_PRP
        discuss_VBP here_RB ,_, although_IN biologically_RB relevant_JJ ,_, are_VBP within_IN
        two_CD fold_VB and_CC might_MD be_VB affected_VBN by_IN small_JJ differences_NNS in_IN
        protein_NN stability_NN ._. Given_VBN this_DT line_NN of_IN reasoning_NN ,_, the_DT data_NNS
        presented_VBN here_RB can_MD be_VB interpreted_VBN as_IN evidence_NN for_IN a_DT cell_NN
        contact_NN (_( density_NN )_) /_NN cell_NN cycle_NN length_NN related_VBD effect_NN on_IN
        transcription_NN that_WDT does_VBZ not_RB affect_VB the_DT retroviral_NN LTR_NNP to_TO
        the_DT extent_NN that_IN it_PRP does_VBZ the_DT htk_NN promoter_NN ._. This_DT effect_NN is_VBZ
        predictive_JJ of_IN the_DT plateau_NN growth_NN phase_NN levels_NNS of_IN Tag_NNP and_CC
        thus_RB ,_, ultimately_RB should_MD affect_VB ,_, in_IN the_DT case_NN of_IN Tag_NNP or_CC
        similar_JJ oncogenes_NNS ,_, the_DT fate_NN of_IN clones_NNS in_IN polyclonal_NN
        populations_NNS ._. For_IN example_NN if_IN an_DT LTR_NNP Tag_NNP line_NN and_CC htk_NN Tag_NNP
        line_NN with_IN equal_JJ expression_NN potential_NN were_VBD co-cultured_JJ ,_, over_IN
        time_NN ,_, one_PRP would_MD expect_VB the_DT LTR_NNP driven_VBN line_NN to_TO dominate_VB ._.
        Finally_RB ,_, the_DT htk_NN lines_NNS here_RB varied_VBD significantly_RB in_IN
        terms_NNS of_IN Tag_NNP expression_NN potential_JJ ,_, and_CC in_IN terms_NNS of_IN the_DT rate_NN
        at_IN which_WDT expression_NN decreased_VBD as_IN a_DT function_NN of_IN cell_NN
        density_NN ._. There_EX was_VBD no_DT correlation_NN in_IN the_DT rate_NN of_IN change_NN in_IN
        density_NN related_VBD expression_NN and_CC the_DT density_NN independent_JJ
        expression_NN (_( here_RB referred_VBD to_TO as_IN intrinsic_JJ expression_NN
        potential_JJ )_) ._. This_DT supports_VBZ the_DT idea_NN that_IN the_DT density_NN
        independent_JJ expression_NN in_IN the_DT htk_NN lines_NNS is_VBZ set_VBN by_IN the_DT clone_NN
        specific_JJ effects_NNS (_( e_SYM ._. g_SYM ._. ,_, integration_NN position_NN )_) and_CC the_DT
        density_NN /_NN cell_NN cycle_NN related_VBD expression_NN is_VBZ set_VBN in_IN these_DT cases_NNS
        by_IN the_DT promoter_NN ._.
      
      
        Conclusions_NNP
        These_DT data_NNS show_VBP quantitatively_RB that_IN the_DT Tag_NNP expression_NN
        potential_NN of_IN introduced_VBN Tag_NNP varies_VBZ over_IN a_DT wide_JJ range_NN
        depending_VBG on_IN the_DT vector_NN used_VBN and_CC clonal_NN variation_NN ._. The_DT
        expression_NN level_NN is_VBZ a_DT complex_JJ measurement_NN that_WDT can_MD be_VB
        partially_RB simplified_VBN by_IN accounting_VBG for_IN the_DT cell_NN cycle_NN
        transit_NN time_NN and_CC cell_NN density_NN ._.
        The_DT hypothetical_JJ terms_NNS ,_, expression_NN at_IN zero_CD cell_NN density_NN
        and_CC expression_NN at_IN minimum_JJ G_NNP 
        1_CD phase_NN fraction_NN ,_, were_VBD introduced_VBN to_TO
        simplify_VB measures_NNS of_IN expression_NN potential_JJ ._.
        Accounting_NNP for_IN both_DT cell_NN cycle_NN transit_NN time_NN and_CC cell_NN
        density_NN should_MD increase_VB the_DT precision_NN and_CC accuracy_NN with_IN
        which_WDT gene_NN expression_NN can_MD be_VB measured_VBN ._. This_DT is_VBZ important_JJ
        for_IN the_DT use_NN of_IN cell_NN lines_NNS as_IN quantitative_JJ standards_NNS for_IN
        gene_NN expression_NN studies_NNS ,_, for_IN relating_VBG expression_NN to_TO
        phenotype_NN ,_, and_CC for_IN an_DT understanding_NN of_IN gene_NN expression_NN in_IN
        general_JJ ,_, and_CC affects_VBZ ideas_NNS on_IN cell_NN engineering_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Generation_NNP of_IN astrocyte_NN cell_NN lines_NNS
          Cortical_NNP astrocytes_NNS were_VBD harvested_VBN from_IN neonatal_NN
          C_NNP 57_CD BL_NNP /_NN 6_CD mice_NNS and_CC infected_VBN with_IN a_DT replication-defective_JJ
          retrovirus_JJ encoding_VBG Tag_NNP and_CC neomycin_NN resistance_NN as_RB
          previously_RB described_VBD [_NN 13_CD ]_NN ._. The_DT transferred_VBN viruses_NNS
          were_VBD SV_NNP 40_CD -_: 6_CD [_NN 5_CD ]_NN ,_, in_IN which_WDT wild_JJ type_NN Tag_NNP is_VBZ expressed_VBN
          from_IN the_DT M-M_NNP uLV_NN LTR_NNP promoter_NN ;_: SV_NNP (_( X_NNP )_) T_NN K_NNP 1_CD ,_, which_WDT is_VBZ
          constructed_VBN the_DT same_JJ as_IN SV_NNP 40_CD -_: 6_CD except_IN that_IN the_DT Tag_NNP is_VBZ
          mutant_JJ [_NN 38_CD ]_NN and_CC defective_JJ for_IN binding_VBG the_DT
          retinoblastoma_NN protein_NN family_NN [_NN 39_CD ]_NN ;_: Linker-tk_NNP T_NN ,_, in_IN
          which_WDT the_DT cDNA_NN for_IN Tag_NNP is_VBZ expressed_VBN from_IN the_DT herpes_NNS
          simplex_NN 1_CD tk_NN promoter_NN [_NN 11_CD ]_NN ._. The_DT differentiation_NN and_CC
          transformation_NN phenotypes_NNS of_IN the_DT cell_NN lines_NNS utilizing_VBG the_DT
          M-M_NNP uLV_NN LTR_NNP promoter_NN have_VBP been_VBN described_VBN [_NN 6_CD 13_CD ]_NN ._. The_DT
          Linker-tk_NNP T_NN lines_NNS (_( tkT_NN )_) were_VBD either_CC isolated_VBN as_IN clones_NNS
          after_IN G_NNP 418_CD selection_NN (_( as_RB previously_RB described_VBD )_) [_NN 6_CD ]_NN or_CC
          frozen_VBN immediately_RB after_IN selection_NN (_( pooled_VBN clones_NNS )_) and_CC
          clonally_RB selected_VBN at_IN a_DT later_JJ time_NN ._. Typically_RB ,_, it_PRP took_VBD 40_CD
          days_NNS after_IN infection_NN to_TO obtain_VB colonies_NNS and_CC 60_CD more_JJR days_NNS
          to_TO generate_VB a_DT rapidly_RB growing_VBG line_NN that_WDT could_MD be_VB serially_RB
          cultured_JJ (_( split_NN 1_CD :_: 80_CD at_IN weekly_JJ intervals_NNS )_) ._. The_DT lines_NNS
          termed_VBD early_JJ passage_NN in_IN this_DT paper_NN were_VBD 140_CD -_: 200_CD days_NNS post_NN
          infection_NN ,_, and_CC all_DT others_NNS were_VBD 340_CD -_: 860_CD days_NNS post_NN
          infection_NN ._. The_DT names_NNS of_IN the_DT cell_NN lines_NNS designate_VB the_DT
          number_NN of_IN days_NNS the_DT primary_JJ neonatal_NN astrocytes_NNS were_VBD
          cultured_JJ prior_RB to_TO infection_NN ._. For_IN example_NN ,_, P_NN 0_CD -_: 17_CD D_NNP #_# 8_CD is_VBZ the_DT
          eighth_JJ clone_NN derived_VBN from_IN cortical_JJ astrocytes_NNS isolated_VBN on_IN
          the_DT day_NN of_IN birth_NN and_CC infected_JJ 17_CD days_NNS later_RB ._. Immortalized_NNP
          cells_NNS were_VBD maintained_VBN in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP medium_NN
          (_( DMEM_NNP ,_, Sigma_NNP ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) with_IN 5_CD %_NN fetal_JJ bovine_JJ serum_NN
          (_( FBS_NNP )_) and_CC 5_CD %_NN calf_NN serum_NN in_IN 5_CD %_NN CO_NNP 
          2_CD at_IN 37_CD °_NN C_NNP ._.
        
        
          Cell_NNP density_NN experiments_NNS
          To_TO test_VB density_NN effects_NNS ,_, cells_NNS were_VBD plated_JJ in_IN
          duplicate_VB at_IN initial_JJ numbers_NNS of_IN 1_CD ,_, 2_CD ,_, 5_CD ,_, 10_CD ,_, 20_CD and_CC 40_CD ×_NN
          10_CD 5_CD per_IN 100_CD mm_NN cell_NN culture_NN dish_NN with_IN DMEM_NNP containing_VBG 5_CD %_NN
          FBS_NNP and_CC 5_CD %_NN calf_NN serum_NN ._. After_IN 2_CD to_TO 3_CD days_NNS of_IN culture_NN ,_,
          cells_NNS were_VBD harvested_VBN with_IN trypsin_NN and_CC counted_VBN on_IN a_DT
          Coulter_NNP Counter_NNP (_( Coulter_NNP Electronics_NNP ,_, Hialeah_NNP ,_, FL_NNP )_) ,_, then_RB
          fixed_VBN for_IN cytometry_NN in_IN 0_CD ._. 5_CD %_NN formaldehyde_NN at_IN 37_CD °_NN C_NNP followed_VBN
          by_IN 95_CD %_NN methanol_NN at_IN -_: 20_CD °_NN C_NNP ._.
        
        
          Cytometry_NNP
          Fixed_NNP samples_NNS were_VBD immunostained_JJ with_IN anti-_NN Tag_NNP ,_, PAb_NNP 416_CD
          (_( Ab_NNP 2_CD ,_, Oncogene_NNP Sciences_NNPS ,_, Mineola_NNP ,_, NY_NNP )_) ,_, and_CC fluorescein_NN
          isothiocyanate_NN (_( FITC_NNP )_) conjugated_JJ secondary_JJ antibody_NN
          followed_VBN by_IN RNase_NNP treatment_NN and_CC propidium_NN staining_VBG at_IN 50_CD
          μg_NN /_NN ml_NN ,_, as_RB previously_RB described_VBD [_NN 13_CD ]_NN ._. Cells_NNP were_VBD
          excited_VBN with_IN the_DT 488_CD nm_NN line_NN of_IN the_DT argon_NN laser_NN of_IN a_DT
          Coulter_NNP ESP_NNP Elite_NNP Cytometer_NNP (_( Coulter_NNP Electronics_NNP ,_, Miami_NNP ,_,
          FL_NNP )_) ._. Final_JJ filters_NNS were_VBD 525_CD nm_NN bandpass_NNS (_( FITC_NNP )_) and_CC 640_CD nm_NN
          long_JJ pass_NN (_( propidium_NN )_) ._. A_DT sample_NN from_IN a_DT large_JJ batch_NN of_IN
          fixed_VBN cells_NNS was_VBD used_VBN to_TO standardize_VB assays_NNS in_IN time_NN ._. This_DT
          sample_NN was_VBD stained_JJ concurrently_RB in_IN each_DT experiment_NN and_CC
          used_VBN to_TO adjust_VB the_DT PMT_NNP 's_POS to_TO the_DT same_JJ FITC_NNP and_CC PI_NNP
          fluorescences_NNS in_IN all_DT experiments_NNS ._. This_DT corrected_VBN for_IN
          differences_NNS in_IN staining_VBG and_CC cytometer_NN set_VBN up_RP ._.
        
        
          Analysis_NNP
          Mean_VB FITC-fluorescence_NNP of_IN the_DT G_NNP 
          1_CD cell_NN cycle_NN phase_NN population_NN was_VBD
          measured_VBN by_IN gating_VBG to_TO generate_VB a_DT statistic_NN that_WDT would_MD be_VB
          independent_JJ of_IN changes_NNS in_IN cell_NN cycle_NN fractions_NNS ._. Mean_VB G_NNP 
          1_CD fluorescence_NN of_IN samples_NNS stained_JJ with_IN
          the_DT anti-_NN Tag_NNP isotype_NN ,_, IgG_NNP 2_CD a_DT ,_, and_CC FITC-conjugated_NNP
          secondary_JJ antibody_NN served_VBD as_IN a_DT control_NN for_IN non-specific_JJ
          fluorescence_NN and_CC was_VBD subtracted_VBN from_IN the_DT G_NNP 
          1_CD fluorescence_NN of_IN corresponding_JJ
          Tag-stained_NNP samples_NNS (_( Figure_NN 4_LS )_) ._. The_DT result_NN of_IN the_DT
          subtraction_NN is_VBZ the_DT Tag_NNP specific_JJ fluorescence_NN and_CC
          corresponds_NNS to_TO the_DT amount_NN of_IN Tag_NNP in_IN the_DT average_JJ G_NNP 
          1_CD cell_NN for_IN a_DT specific_JJ population_NN ._.
          Forward_NNP and_CC right_JJ angle_NN light_JJ scatter_NN were_VBD used_VBN to_TO gate_NN
          debris_NN ._. Modeling_NNP software_NN (_( ModFit_NNP ,_, Verity_NNP Software_NNP House_NNP ,_,
          Topsham_NNP ,_, ME_NNP )_) was_VBD used_VBN to_TO determine_VB the_DT phase_NN fractions_NNS
          from_IN analysis_NN of_IN single_JJ parameter_NN DNA_NNP data_NNS ._. Linear_NNP
          regression_NN ,_, using_VBG GraphPad_NNP Prism_NNP version_NN 3_CD ._. 00_CD for_IN Windows_NNP
          (_( GraphPad_NNP Software_NNP ,_, San_NNP Diego_NNP California_NNP USA_NNP ,_,
          www_NN ._. graphpad_NN ._. com_NN )_) ,_, was_VBD used_VBN to_TO determine_VB the_DT slope_NN ,_,
          standard_JJ error_NN (_( SE_NNP )_) ,_, and_CC p-value_JJ for_IN Tag_NNP expression_NN as_IN a_DT
          function_NN of_IN cell_NN density_NN or_CC the_DT frequency_NN of_IN G_NNP 
          1_CD cells_NNS ._.
        
        
          Electrophoresis_NNP and_CC western_JJ blotting_VBG
          Cell_NNP extracts_NNS were_VBD prepared_VBN in_IN 10_CD %_NN SDS_NNP lysis_NNS buffer_NN
          (_( 0_CD ._. 137_CD M_NNP NaCl_NNP ,_, 2_CD %_NN Nonidet_NNP P-_NNP 40_CD ,_, 10_CD %_NN SDS_NNP ,_, 1_CD %_NN sodium_NN
          deoxycholate_NN ,_, 20_CD mM_NN Tris_NNP ,_, pH_NN 8_CD ._. 0_CD ,_, 2_CD mM_NN PMSF_NNP ,_, 10_CD μl_NN /_NN ml_NN
          protease_NN inhibitor_NN cocktail_NN )_) ,_, which_WDT solubilizes_NNS
          cytoskeletal_NN and_CC nuclear_JJ matrices_NNS ._. Samples_NNP of_IN known_VBN
          numbers_NNS of_IN cells_NNS from_IN the_DT cell_NN lines_NNS and_CC recombinant_JJ ,_,
          purified_JJ Tag_NNP prepared_VBD from_IN a_DT baculovirus_JJ lysate_NN [_NN 40_CD ]_NN
          were_VBD loaded_VBN on_IN 10_CD %_NN polyacrylamide_NN discontinuous_JJ mini-gels_JJ
          (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) and_CC electrophoresed_JJ
          conventionally_RB [_NN 41_CD ]_NN ._. Gels_NNP were_VBD then_RB
          electrophoretically_RB blotted_JJ [_NN 42_CD ]_NN onto_IN PVDF_NNP membrane_NN
          (_( Bio-_NNP Rad_NNP )_) without_IN methanol_NN for_IN 15_CD min_NN at_IN 100_CD V_NNP ._. Tag_NNP was_VBD
          visualized_JJ by_IN immunostaining_VBG with_IN PAb_NNP 416_CD and_CC alkaline_NN
          phosphatase_NN conjugated_JJ secondary_JJ antibody_NN (_( Sigma_NNP )_) using_VBG
          chemiluminescent_NN detection_NN with_IN CDP-Star_NNP substrate_NN
          according_VBG to_TO the_DT manufacturers_NNS directions_NNS (_( Tropix_NNP ,_,
          Bedford_NNP ,_, MA_NNP )_) ._. Images_NNP were_VBD developed_VBN on_IN X-_NNP ray_NN film_NN (_( Kodak_NNP ,_,
          X-O_NNP mat_NN ,_, Rochester_NNP ,_, NY_NNP )_) ._. Quantification_NNP was_VBD performed_VBN by_IN
          densitometry_NN on_IN the_DT Sci_NNP Scan_NNP 5000_CD automated_VBN scanning_VBG
          system_NN (_( US_NNP Biochemicals_NNP ,_, Cleveland_NNP ,_, OH_NNP )_) ._.
          To_TO test_VB for_IN astrocyte_NN lineage_NN ,_, early_JJ passage_NN cells_NNS
          were_VBD grown_VBN in_IN dibutyryl_NN cAMP_NN (_( Sigma_NNP )_) to_TO enhance_VB GFAP_NNP
          expression_NN ._. Intermediate_NNP filament_NN extracts_NNS of_IN the_DT cell_NN
          lines_NNS [_NN 43_CD 44_CD ]_NN were_VBD electrophoretically_RB blotted_JJ and_CC
          detected_VBD with_IN polyclonal_NN anti_NN GFAP_NNP (_( DAKO_NNP ,_, Carpenteria_NNP ,_,
          CA_NNP )_) and_CC secondary_JJ reagents_NNS as_IN above_IN ._.
        
      
    
  
